Scilex Holding (SCLX) Assets Average (2021 - 2026)
Scilex Holding (SCLX) posted quarterly Assets Average of $329.3 million for Q1 2026, up 283.07% year-over-year from $86.0 million in Q1 2025, and up 2.77% quarter-over-quarter from $320.4 million in Q4 2025.
Scilex Holding (SCLX) Assets Average (2021 - 2026) Analysis & Trends
Scilex Holding's Assets Average history runs 6 years deep, the most recent figure standing at $329.3 million for Q1 2026.
- In Q1 2026, Assets Average rose 283.07% year-over-year to $329.3 million; the TTM figure through Mar 2026 stood at $329.3 million (up 283.07% YoY), while the FY2025 annual figure was $229.0 million, up 135.73% from the prior year.
- Assets Average for Q1 2026 stood at $329.3 million, up from $320.4 million in the prior quarter.
- The five-year high for Assets Average was $329.3 million in Q1 2026, with the low at $81.4 million in Q2 2025.
- The 5-year median for Assets Average is $102.5 million (2024), against an average of $132.0 million.
- The sharpest annual moves came in 2023 and 2026: Assets Average declined 24.98% in 2023, then soared 283.07% in 2026.
- Scilex Holding's Assets Average stood at $94.0 million in 2022, then declined by 3.27% to $90.9 million in 2023, then grew by 6.35% to $96.7 million in 2024, then jumped by 231.39% to $320.4 million in 2025, then climbed by 2.77% to $329.3 million in 2026.
- Business Quant data shows SCLX's Assets Average at $329.3 million in Q1 2026, $320.4 million in Q4 2025, and $179.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 653.18 Bn | 632.42 Bn | 17.26 Bn | 200.98 Bn |
| 2 | AbbVie | 470.13 Bn | 463.56 Bn | 12.70 Bn | 135.79 Bn |
| 3 | Merck | 376.16 Bn | 369.02 Bn | 12.21 Bn | 129.24 Bn |
| 4 | Novartis Ag | 302.69 Bn | 295.00 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.73 Bn | 252.83 Bn | 12.86 Bn | 114.92 Bn |
| 6 | Amgen | 236.53 Bn | 222.54 Bn | 7.24 Bn | 94.07 Bn |
| 7 | Gilead Sciences | 183.21 Bn | 180.03 Bn | 6.22 Bn | 52.82 Bn |
| 8 | Pfizer | 160.17 Bn | 148.47 Bn | 10.94 Bn | 204.57 Bn |
| 9 | Gsk | 105.91 Bn | 101.75 Bn | 8.24 Bn | 83.80 Bn |
| 10 | Scilex Holding | 39.90 Mn | -72.88 Mn | 3.97 Mn | 251.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 329.31 Mn |
| Dec 31, 2025 | 320.43 Mn |
| Sep 30, 2025 | 179.82 Mn |
| Jun 30, 2025 | 81.37 Mn |
| Mar 31, 2025 | 85.96 Mn |
| Dec 31, 2024 | 96.69 Mn |
| Sep 30, 2024 | 102.49 Mn |
| Jun 30, 2024 | 97.89 Mn |
| Mar 31, 2024 | 96.27 Mn |
| Dec 31, 2023 | 90.92 Mn |
| Sep 30, 2023 | 103.50 Mn |
| Jun 30, 2023 | 106.26 Mn |
| Mar 31, 2023 | 86.29 Mn |
| Dec 31, 2022 | 93.99 Mn |
| Sep 30, 2022 | 121.88 Mn |
| Jun 30, 2022 | 141.64 Mn |
| Mar 31, 2022 | 109.45 Mn |
| Dec 31, 2021 | 108.79 Mn |
| Sep 30, 2021 | 139.77 Mn |
| Jun 30, 2021 | 139.98 Mn |